| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Advances in Genomic and Proteomic Studies of Non–Small-Cell Lung Cancer: Clinical and Translational Research Perspective
|
Dziadziuszko, Rafal
|
|
2008
|
9 |
2 |
p. 78-84
7 p.
|
article
|
| 2 |
Bevacizumab/Chemotherapy in Non–Small-Cell Lung Cancer: Looking for A Few Good Men?
|
Herbst, Roy S.
|
|
2008
|
9 |
2 |
p. 75-76
2 p.
|
article
|
| 3 |
Complications of Ablative Therapies in Lung Cancer
|
Padda, Sukhmani
|
|
2008
|
9 |
2 |
p. 122-126
5 p.
|
article
|
| 4 |
Cooperative Group Portfolio in Locally Advanced Non–Small-Cell Lung Cancer: Are We Making Progress?
|
Langer, Corey J.
|
|
2008
|
9 |
2 |
p. 85-91
7 p.
|
article
|
| 5 |
Errata
|
|
|
2008
|
9 |
2 |
p. 77-
1 p.
|
article
|
| 6 |
High Incidence of Lung Cancer After Non–Muscle-Invasive Transitional Cell Carcinoma of the Bladder: Implications for Screening Trials
|
Rusthoven, Kyle E.
|
|
2008
|
9 |
2 |
p. 106-111
6 p.
|
article
|
| 7 |
Management of Unresectable Stage III Non–Small-Cell Lung Cancer with Combined-Modality Therapy: A Review of the Current Literature and Recommendations for Treatment
|
Bayman, Neil A.
|
|
2008
|
9 |
2 |
p. 92-101
10 p.
|
article
|
| 8 |
Population Characteristics and Prognostic Factors in Metastatic Non–Small-Cell Lung Cancer: A Fox Chase Cancer Center Retrospective
|
Paralkar, Vikram R.
|
|
2008
|
9 |
2 |
p. 116-121
6 p.
|
article
|
| 9 |
Restrictive Eligibility Limits Access to Newer Therapies in Non–Small-Cell Lung Cancer: The Implications of Eastern Cooperative Oncology Group 4599
|
Somer, Robert A.
|
|
2008
|
9 |
2 |
p. 102-105
4 p.
|
article
|
| 10 |
Selected Clinical Trials in Lung Cancer
|
Langer, Corey J.
|
|
2008
|
9 |
2 |
p. 127-128
2 p.
|
article
|
| 11 |
Thrombin-Activatable Fibrinolysis Inhibitor Levels in Patients with Non–Small-Cell Lung Cancer
|
Koldas, Macit
|
|
2008
|
9 |
2 |
p. 112-115
4 p.
|
article
|
Journal description